Advanced search
Publication Cover
Clinical Toxicology Volume 54, 2016 - Issue 6
Submit an article Journal homepage
1,866
Views
24
CrossRef citations to date
0
Altmetric
Clinical Research

Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1)

Betty S. ChanClinical Toxicology Unit and Emergency Department, Prince of Wales Hospital, Sydney, New South Wales, Australia; ;New South Wales Poisons Information Centre, Sydney Children's Hospital at Westmead, Sydney, New South Wales, Australia; Correspondence[email protected]
,
Geoffrey K. IsbisterNew South Wales Poisons Information Centre, Sydney Children's Hospital at Westmead, Sydney, New South Wales, Australia; ;Clinical Toxicology Research Group, University of Newcastle, Newcastle, Australia; ;Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, Newcastle, Australia;
,
Margaret O’LearyClinical Toxicology Research Group, University of Newcastle, Newcastle, Australia; ;Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, Newcastle, Australia;
,
Angela ChiewClinical Toxicology Unit and Emergency Department, Prince of Wales Hospital, Sydney, New South Wales, Australia; ;New South Wales Poisons Information Centre, Sydney Children's Hospital at Westmead, Sydney, New South Wales, Australia;
&
Nicholas A. BuckleyNew South Wales Poisons Information Centre, Sydney Children's Hospital at Westmead, Sydney, New South Wales, Australia; ;Department of Clinical Pharmacology, University of Sydney, Sydney, New South Wales, Australia
Pages 488-494 | Received 15 Nov 2015, Accepted 31 Mar 2016, Published online: 27 Apr 2016

References

  • Chugh SS, Havmoeller R Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129:837–847.
  • Wyse DG, Waldo AL DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833.
  • Roberts DM, Galappatthy G, Dunuwille A, et al. Pharmacological treatment of cardiac glycoside poisoning. Br J Clin Pharmacol. 2016;81:488–495.
  • Hauptman PJ, McCann P, Romero JM, et al. Reference laboratory values for digoxin following publication of Digitalis Investigation Group (DIG) trial data. JAMA Int Med. 2013;173:1552–1554.
  • Bateman DN. Digoxin-specific antibody fragments: how much and when? Toxicol Rev. 2004;23:135–143.
  • Lapostolle F, Borron SW Verdier C, et al. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Intensive Care Med. 2008;34:1448–1453.
  • Flanagan RJ, Jones AL. Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27:1115–1133.
  • Kirkpatrick CH. Allergic histories and reactions of patients treated with digoxin immune Fab (ovine) antibody. The digibind study advisory panel. Am J Emerg Med. 1991;9:7–10.
  • Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila). 2014;52:824–836.
  • Cheng JW, Charland SL Shaw LM, et al. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay. Pharmacotherapy. 1997;17:584–590.
  • Martin-Suarez A, Lanao JM, Calvo MV, et al. Digoxin pharmacokinetics in patients with high serum digoxin concentrations. J Clin Pharm Ther. 1993;18:63–68.
  • Taboulet P, Baud FJ, Bismuth C . Clinical features and management of digitalis poisoning – rationale for immunotherapy. J Toxicol Clin Toxicol. 1993;31:247–260.
  • Umans VA, Cornel JH, Hic C. Digoxin in patients with heart failure. New Engl J Med. 1997;337:129.
  • Sanchez de la Rosa R, Rodriguez Hernandez N, Cueto Guerreiro T, et al. Epidemiological surveillance of patients treated with digoxin. Arch Inst Cardiol Mex. 1996;66:510–518.
  • Kulawickrama S, O'Leary MA, Hodgson WC, et al. Development of a sensitive enzyme immunoassay for measuring taipan venom in serum. Toxicon. 2010;55:1510–1518.
  • Eyer F, Steimer W, Muller C, et al. Free and total digoxin in serum during treatment of acute digoxin poisoning with Fab fragments: case study. Am J Crit Care. 2010;19:391–387.
  • Pita-Fernandez S, Lombardia-Cortina M, Orozco-Veltran D, et al. Clinical manifestations of elderly patients with digitalis intoxication in the emergency department. Arch Gerontol Geriatr. 2011;53:e106–e110.
  • Hornestam B, Jerling M, Karlsson MO, et al. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the digitalis in acute atrial fibrillation trial. Eur J Clin Pharmacol. 2003;58:747–755.
  • Antman EM, Wenger TL, Butler VP, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81:1744–1752.
  • Hickey AR, Wenger TL Carpenter VP, et al. Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991;17:590–598.
  • Schaeffer TH, Mlynarchek SL Stanford CF, et al . Treatment of chronically digoxin-poisoned patients with a newer digoxin immune fab – a retrospective study. J Am Osteopath Assoc. 2010;110:587–592.
  • Bilbault P, Oubaassine R Rahmani H, et al. Emergency step-by-step specific immunotherapy in severe digoxin poisoning: an observational cohort study. Eur J Emerg Med. 2009;16:145–149.
  • Cano NJ, Sabouraud AE, Debray M, et al. Dose-dependent reversal of digoxin-inhibited activity of an in vitro Na + K+ATPase model by digoxin-specific antibody. Toxicol Lett. 1996;85:107–111.
  • Sinclair AJ, Hewick DS, Johnston PC, et al. Kinetics of digoxin and anti-digoxin antibody fragments during treatment of digoxin toxicity. Br J Clin Pharmacol. 1989;28:352–356.
  • Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet. 1995;28:483–493.
  • Ujhelyi MR, Robert S Cummings DM, et al. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin. Ann Intern Med. 1993;119:273–277.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.